PDF(Pubmed)
Abstract：
UNASSIGNED: The 2021 World Health Organization Classification of Central Nervous System Tumors updates glioma subtyping and grading system, and incorporates EGFR amplification (Amp) as one of diagnostic markers for glioblastoma (GBM).
UNASSIGNED: This study aimed to describe the frequency, clinical value and molecular correlation of EGFR Amp in diffuse gliomas based on the latest classification.
UNASSIGNED: We reviewed glioma patients between 2011 and 2022 at our hospital, and included 187 adult glioma patients with available tumor tissue for detection of EGFR Amp and other 59 molecular markers of interest. Clinical, radiological and pathological data was analyzed based on the status of EGFR Amp in different glioma subtypes.
UNASSIGNED: 163 gliomas were classified as adult-type diffuse gliomas, and the number of astrocytoma, oligodendroglioma and GBM was 41, 46, and 76. EGFR Amp was more common in IDH-wildtype diffuse gliomas (66.0%) and GBM (85.5%) than IDH-mutant diffuse gliomas (32.2%) and its subtypes (astrocytoma, 29.3%; oligodendroglioma, 34.8%). EGFR Amp did not stratify overall survival (OS) in IDH-mutant diffuse gliomas and astrocytoma, while was significantly associated with poorer OS in IDH-wildtype diffuse gliomas, histologic grade 2 and 3 IDH-wildtype diffuse astrocytic gliomas and GBM.
UNASSIGNED: Our study validated EGFR Amp as a diagnostic marker for GBM and still a useful predictor for shortened OS in this group.
UNASSIGNED: This study aimed to describe the frequency, clinical value and molecular correlation of EGFR Amp in diffuse gliomas based on the latest classification.
UNASSIGNED: We reviewed glioma patients between 2011 and 2022 at our hospital, and included 187 adult glioma patients with available tumor tissue for detection of EGFR Amp and other 59 molecular markers of interest. Clinical, radiological and pathological data was analyzed based on the status of EGFR Amp in different glioma subtypes.
UNASSIGNED: 163 gliomas were classified as adult-type diffuse gliomas, and the number of astrocytoma, oligodendroglioma and GBM was 41, 46, and 76. EGFR Amp was more common in IDH-wildtype diffuse gliomas (66.0%) and GBM (85.5%) than IDH-mutant diffuse gliomas (32.2%) and its subtypes (astrocytoma, 29.3%; oligodendroglioma, 34.8%). EGFR Amp did not stratify overall survival (OS) in IDH-mutant diffuse gliomas and astrocytoma, while was significantly associated with poorer OS in IDH-wildtype diffuse gliomas, histologic grade 2 and 3 IDH-wildtype diffuse astrocytic gliomas and GBM.
UNASSIGNED: Our study validated EGFR Amp as a diagnostic marker for GBM and still a useful predictor for shortened OS in this group.
摘要：
■2021年世界卫生组织中枢神经系统肿瘤分类更新了神经胶质瘤亚型和分级系统，并将EGFR扩增（Amp）作为胶质母细胞瘤（GBM）的诊断标志物之一。
■本研究旨在描述频率，基于最新分类的EGFRAmp在弥漫性胶质瘤中的临床价值和分子相关性。
■我们回顾了2011年至2022年在我们医院的神经胶质瘤患者，其中包括187名成人神经胶质瘤患者，有可用的肿瘤组织用于检测EGFRAmp和其他59个感兴趣的分子标志物。临床,根据EGFRAmp在不同胶质瘤亚型中的状态分析影像学和病理学资料。
■163个胶质瘤被分类为成人型弥漫性胶质瘤，星形细胞瘤的数量，少突胶质细胞瘤和GBM分离为41、46和76。EGFRAmp在IDH野生型弥漫性神经胶质瘤（66.0％）和GBM（85.5％）中比IDH突变型弥漫性神经胶质瘤（32.2％）及其亚型（星形细胞瘤，29.3%;少突胶质细胞瘤,34.8%）。EGFRAmp未对IDH突变型弥漫性神经胶质瘤和星形细胞瘤的总生存期（OS）进行分层，虽然与IDH野生型弥漫性神经胶质瘤的OS较差显著相关，组织学2级和3级IDH-野生型弥漫性星形胶质细胞瘤和GBM。
■我们的研究验证了EGFRAmp是GBM的诊断标志物，并且仍然是该组中OS缩短的有用预测因子。
■本研究旨在描述频率，基于最新分类的EGFRAmp在弥漫性胶质瘤中的临床价值和分子相关性。
■我们回顾了2011年至2022年在我们医院的神经胶质瘤患者，其中包括187名成人神经胶质瘤患者，有可用的肿瘤组织用于检测EGFRAmp和其他59个感兴趣的分子标志物。临床,根据EGFRAmp在不同胶质瘤亚型中的状态分析影像学和病理学资料。
■163个胶质瘤被分类为成人型弥漫性胶质瘤，星形细胞瘤的数量，少突胶质细胞瘤和GBM分离为41、46和76。EGFRAmp在IDH野生型弥漫性神经胶质瘤（66.0％）和GBM（85.5％）中比IDH突变型弥漫性神经胶质瘤（32.2％）及其亚型（星形细胞瘤，29.3%;少突胶质细胞瘤,34.8%）。EGFRAmp未对IDH突变型弥漫性神经胶质瘤和星形细胞瘤的总生存期（OS）进行分层，虽然与IDH野生型弥漫性神经胶质瘤的OS较差显著相关，组织学2级和3级IDH-野生型弥漫性星形胶质细胞瘤和GBM。
■我们的研究验证了EGFRAmp是GBM的诊断标志物，并且仍然是该组中OS缩短的有用预测因子。
